Triaxial Accelerometer & Algorithm development

The National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services, is seeking to procure a comprehensive technological solution for pediatric movement and clinical assessment. The project involves developing a triaxial accelerometer wearable device capable of measuring physical activity, posture, and upper extremity movements, with specific requirements including pediatric-friendly wrist band/pendant options and a two-week battery life. Additionally, the contract calls for an electronic clinical outcomes assessment platform that can capture quantitative speech and vision impairment data using validated algorithms through a FedRAMP-compliant cloud infrastructure. Potential vendors must submit their 10-page electronic responses to Frederick Weddington by January 21, 2025, at 9:00 am ET, addressing each requirement separately and providing comprehensive company details, employee counts, and qualifications. The evaluation will likely focus on technical capabilities, compliance with specified device and algorithm requirements, and demonstrated expertise in pediatric research technologies.

This pre-solicitation notice is designated as a Total Small Business set-aside under NAICS category 541990 (All Other Professional, Scientific, and Technical Services), with a $19M size standard. The anticipated contract structure includes one base year and four potential one-year option periods, suggesting a potential total contract duration of five years. While no incumbent contractors are specified in the documentation, interested firms with relevant GSA Schedule contracts may have a competitive advantage. The project's scope encompasses not just hardware development but also sophisticated algorithm creation and data analytics services for interpreting pediatric movement and clinical data. Although the exact award value is not explicitly stated, the comprehensive nature of the requirements and the specified NAICS size standard indicate a significant potential investment in advanced medical research technology.